A UK court accepted an application by Premaitha to include an antitrust claim in its defense, and has tentatively scheduled the trial for the summer of 2017.
The agreement marks the sixth Iona distribution deal Premaitha has signed with regional partners in recent months, including ones in France and India.
St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.
Visional Medical will begin offering the test, which estimates the risk of a fetus being affected by Down syndrome and other genetic conditions, in India.
The recommendation calls for NIPT to be initially offered to women deemed at high risk for trisomy 21, 13, or 18 after the initial screening test.
The company has sued three companies in the UK and two in Poland alleging they infringed on the firm's non-invasive prenatal testing patents.
Thermo will invest £5 million in Premaitha as a secured loan facility, of which the firm will receive £3 million initially and the remainder as milestone payments.
Adgenix has already signed up its first laboratory customer, inking a contract for a minimum of three years to supply LaboSud with the assay.
The demonstration project at the Wolfson Institute aims to assess the cost-effectiveness, uptake, and outcomes of the Iona test when offered as a reflex test.
The allaince will enable Greek labs to offer for the first time a non-invasive prenatal screening test locally, rather than sending samples out of the country.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.